Showing results (501-510 of 782) with videos related to
Sort By:
Pageof 79
British Journal of Haematology|August 21, 2008
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myelomaSagar Lonial, Paul G Richardson, Jesús San Miguel, et al.Blood|January 18, 2003
Molecular sequelae of histone deacetylase inhibition in human malignant B cellsNicholas Mitsiades, Constantine S Mitsiades, Paul G Richardson, et al.Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2011
Management of relapsed and relapsed/refractory multiple myelomaJacob P Laubach, Constantine S Mitsiades, Anuj Mahindra, et al.Cancers|January 13, 2019
Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in OncogenesisMatthew Ho Zhi Guang, Emma L Kavanagh, Luke Paul Dunne, et al.Blood|April 9, 2005
A clinically relevant SCID-hu in vivo model of human multiple myelomaPierfrancesco Tassone, Paola Neri, Daniel R Carrasco, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2017
Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateCharles A Schiffer, Kari Bohlke, Meghan Delaney, et al.Blood Cancer Journal|March 28, 2019
Deciphering the chronology of copy number alterations in Multiple MyelomaAnil Aktas Samur, Stephane Minvielle, Masood Shammas, et al.Clinical and Experimental Medicine|July 8, 2023
Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugsXili Liu, Maria Moscvin, Seungeun Oh, et al.Blood Cancer Journal|December 19, 2022
In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factorsAnil Aktas Samur, Mariateresa Fulciniti, Herve Avet-Loiseau, et al.Oncogene|March 1, 2005
Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitorsTeru Hideshima, Dharminder Chauhan, Kenji Ishitsuka, et al.Pageof 79